Orthocell

10/04/2026

Orthocell are proud to sponsor the prestigious Premier's Science Awards, celebrating excellence across science, technology, engineering and mathematics in Western Australia.

Now in its 25th year, the awards recognise the researchers, educators and innovators driving progress and shaping the future of STEM.

We are committed to supporting innovation, advancing scientific outcomes and contributing to a thriving global research community.

We look forward to celebrating the incredible talent and achievements within WA’s STEM sector.

🔗 Learn more: https://bit.ly/4mqZY3c

$OCC

09/04/2026

📰 Media | StockwireX

Orthocell’s nerve repair product, Remplir™, has been highlighted in recent coverage by StockwireX, outlining its exemption from newly introduced US tariffs on medical devices.

The article reinforces the strategic importance of Remplir within the US market, with the exemption supporting continued access to this innovative nerve repair solution without additional cost burden.

As Orthocell advances its commercialisation efforts in the United States, this development further strengthens the Company’s position and ability to scale globally.

Orthocell Managing Director Paul Anderson said:
“The exemption ensures that Remplir remains competitively positioned in the US ...and supports our mission to deliver effective nerve repair solutions to patients and surgeons without disruption.”

Take a look: https://bit.ly/4c0Kcsf

$OCC

02/04/2026

Ignite Investment Summit | Hong Kong
15-16 April 2026

Orthocell (ASX: OCC) CEO and Managing Director Paul Anderson, together with Chairman John Van Der Wielen, will be attending the Ignite Investment Summit in Hong Kong next week.

The Summit brings together company leaders and institutional investors from across the APAC region for two days of targeted meetings, presentations and investor engagement.

Paul will present an update on Orthocell’s growth strategy, including the continued US commercialisation of Remplir™ and the Company’s broader global expansion.

The event provides an important opportunity to connect with international investors and further expand Orthocell’s presence across key capital markets.

Register for the event and book a meeting with $OCC here: https://weareignite.com/events/april-2026/

01/04/2026

Replay | Ausbiz Capital Investor Connect

Orthocell CEO and Managing Director Paul Anderson presented today at the Ausbiz Capital Investor Connect Biotech & Pharmaceuticals Special, where he provided an update on the Company’s commercial progress and global expansion strategy.

The presentation focused on the US rollout of Remplir™, where market access activities continue to progress as planned, supported by growing surgeon adoption and increasing sales momentum.

With expanding distribution, advancing VAC approvals and growing repeat usage, Orthocell remains focused on disciplined ex*****on as it scales its presence in the US nerve repair market.

Take a look: https://bit.ly/4sccjcL

29/03/2026

Upcoming Investor Events

Orthocell CEO and MD Paul Anderson will be presenting at the following investor events, outlining the Company’s global expansion strategy and the commercialisation of Remplir™ in the United States.

👉 Life Sciences WA | Broker Meets Biotech
🗓️ 31 March
⏰ 1.00pm -3.30pm AWST

More information coming soon here: https://bit.ly/3Puiviy

👉 Ausbiz | Capital Investor Connects
🗓️ 31 March
⏰ 9am AWST

Register your spot today: https://bit.ly/4bQeMDx

👉 Hong Kong Ignite Investment Summit
🗓️ 15 - 16 April 2026
📍 Grand Hyatt, Wan Chai | Hong Kong

If you're interested in scheduling a 30-minute meeting with Orthocell, please register here: https://weareignite.com/investor/

Join the sessions to learn more on the Company’s progress and future outlook.

$OCC

26/03/2026

📰 Media | The Armchair Analyst

Surgeon engagement is at the heart of Orthocell’s commercialisation approach. Clinical data and regulatory approvals are critical, but ultimately, adoption happens in practice. It comes down to whether a surgeon chooses to incorporate a product into their workflow, and use it consistently.

A recent article in The Armchair Analyst explores this dynamic through the reflections of an experienced surgeon, “Surgeon Dan,” using Orthocell’s Remplir™.

Here’s an excerpt:

“Getting surgeons to switch products can be hard.

We get used to doing procedures in our own way, with our own product set.

So new products that come to market looking to displace existing products, can’t just be equivalent.

They need to be markedly better for a surgeon to make the switch.

Alternatively, if there is a true unmet need, then adopting those products is a much easier decision.

That is what I saw when two Orthocell (ASX: OCC) reps came into my practice three weeks ago to demonstrate Remplir’s ability to restore erectile nerve function for men who have had prostate cancer.

Because this is a true unmet need.“

It’s worth a read: https://bit.ly/4t93r8A

$OCC

20/03/2026

Did you catch Paul Anderson’s recent interview with Proactive?

He shares how Orthocell’s flagship nerve repair product, Remplir™, is being used by trauma surgeons in Ukraine to support the treatment of complex, combat-related nerve injuries. It is a powerful example of regenerative medicine making a tangible difference in high-pressure clinical settings.

Paul also touches on the growing global opportunity for Remplir, with adoption continuing to build across key international markets and surgical applications where outcomes truly matter.

Take a look 👉 https://bit.ly/4t0mmCw

Orthocell Ltd managing director Paul Anderson talked with Proactive about the company’s Remplir™ nerve repair device and its recent real-world application in...

20/03/2026

📰 $OCC In the News

Orthocell’s flagship nerve repair product, Remplir™, is being used to treat injured soldiers in Ukraine, as highlighted in a recent article by The Australian.

The piece underscores the real-world impact of Orthocell's regenerative medicine technology in complex trauma cases, where effective nerve repair can be critical to recovery.

With Remplir already approved across key global markets including Australia, the US, Canada, Singapore and Hong Kong, this milestone reflects the growing international adoption of Orthocell’s solutions in high-need environments.

Orthocell Managing Director Paul Anderson said:

"In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant.”

“The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution."

Read the article here: https://bit.ly/4bl8j4q

Special Report: Perth-based regenerative medicine company Orthocell’s flagship nerve repair device Remplir has been used in 23 surgical procedures on injured soldiers in Ukraine.

19/03/2026

Device Technologies, the Orthocell Remplir™ distributor across Australia, NZ & Singapore, teamed up with Orthocell to attend the 2026 Australasian Plastic and Reconstructive Surgery SET Registrars Conference.

Trevor Turnbull from Orthocell and Seamus Young from Device Technologies have enjoyed meeting the Plastic and Reconstructive Surgery Registrars and discussing the application of Remplir nerve wraps in hand surgery, microsurgery, trauma, and reconstructive surgery.

Well done to the Australian Society of Plastic Surgeons for putting on a great conference in Perth.

hashtag hashtag hashtag hashtag hashtag

18/03/2026

Last year, as part of a humanitarian initiative, Orthocell coordinated the delivery of nerve repair device Remplir™ to volunteer trauma surgeons supporting frontline medical care in Ukraine. Orthocell has now received confirmation that the device has been successfully used in 23 surgical procedures on injured soldiers.

Ukrainian surgeons were supported through remote video training delivered by Australian Orthopaedic Surgeon and Orthocell Key Opinion Leader Dr Alex O’Beirne. The Company will continue working with Ukrainian clinicians to monitor patient outcomes and, where possible, collect clinical data to support engagement with defence organisations globally.

Orthocell Managing Director Paul Anderson said:

“In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant. The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution.”

Orthocell would like to acknowledge the contribution of Ukrainian Ambassador to Australia, Vasyl Myroshnychenko, who has played an important role in facilitating engagement and coordination with Ukrainian stakeholders.

Read the ASX announcement: https://bit.ly/4cPdNFN

$OCC

16/03/2026

Device Technologies and Orthocell teams came together at the Australian Hand Surgery Society Annual Scientific Meeting in Melbourne last week.

Gregor, Hamish, Eimear and Ellis from Orthocell were joined at the booth by Sue and Natasha (all pictured), as well as Jordan & Renee from Device Technologies, the distributor of Remplir™ in Australia, New Zealand and Singapore.

It was great connecting with hand surgeons and discussing the applications of Remplir™ in upper limb and nerve repair surgery.

10/03/2026

Today, Orthocell is at the 2026 Australian Hand Surgery Society Annual Scientific Meeting in Melbourne.🚋

Make sure you are at the Scientific Session 1 – Nerve, Paediatrics & Experimental Models, on Thursday 12th March to see:

⏰ 08:50 am | Dr Georgia Calvert | Outcomes of epineurium-like nerve wrap in primary and revision carpal and cubital tunnel surgery.

⏰ 09:24 am | Professor Minghao Zheng | Gold nanoparticle-coated epineurial collagen substitute promotes neurite outgrowth and modulates Schwann cell function.

Also looking forward to hearing Dr Amber Leis, international guest speaker and Residency Program Director - Plastic Surgery from Washington University in St. Louis, USA.

Meet the Orthocell team at Booth #10. Talk to Gregor, Hamish, Ellis, Eimear, and our Founder & MD, Paul Anderson. Get to feel, in your own hands, the exceptional handling characteristics of Remplir™, our collagen nerve wrap.